Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does RIBOCICLIB Cause Concomitant disease aggravated? 108 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 108 reports of Concomitant disease aggravated have been filed in association with RIBOCICLIB (KISQALI). This represents 0.4% of all adverse event reports for RIBOCICLIB.

108
Reports of Concomitant disease aggravated with RIBOCICLIB
0.4%
of all RIBOCICLIB reports
18
Deaths
60
Hospitalizations

How Dangerous Is Concomitant disease aggravated From RIBOCICLIB?

Of the 108 reports, 18 (16.7%) resulted in death, 60 (55.6%) required hospitalization, and 28 (25.9%) were considered life-threatening.

Is Concomitant disease aggravated Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for RIBOCICLIB. However, 108 reports have been filed with the FAERS database.

What Other Side Effects Does RIBOCICLIB Cause?

Neutropenia (3,585) Nausea (3,404) Fatigue (3,327) Malignant neoplasm progression (2,468) Death (2,452) Vomiting (1,953) Diarrhoea (1,830) White blood cell count decreased (1,683) Pain (1,637) Metastases to bone (1,538)

What Other Drugs Cause Concomitant disease aggravated?

SACUBITRIL\VALSARTAN (533) SECUKINUMAB (461) FINGOLIMOD (425) MACITENTAN (286) OMALIZUMAB (186) SELEXIPAG (166) METHOTREXATE (150) RUXOLITINIB (142) OCTREOTIDE (125) BOSENTAN (123)

Which RIBOCICLIB Alternatives Have Lower Concomitant disease aggravated Risk?

RIBOCICLIB vs RIBOFLAVIN RIBOCICLIB vs RIBOFLAVIN 5'-PHOSPHATE RIBOCICLIB vs RIBOFLAVIN 5^-PHOSPHATE RIBOCICLIB vs RIFABUTIN RIBOCICLIB vs RIFAMPICIN

Related Pages

RIBOCICLIB Full Profile All Concomitant disease aggravated Reports All Drugs Causing Concomitant disease aggravated RIBOCICLIB Demographics